RxDoctor Payments Data

Philip Kim, MD

Family Medicine · Torrance, CANPI 1356781132

Payments from drug & device makers

$394,199in general payments, 2019–2025

Across 119 payments — averaging $3312.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cleerly, Inc.$312K
  • Novartis$78K
  • Envista Holdings Corporation$750
  • Biohaven Pharmaceutical Holding Company Ltd.$506
  • Johnson & Johnson$367
  • Novo Nordisk$350
  • plus $2K from 21 others

What the payments were for

  • Consulting fees$75019%
  • Travel & lodging$2286%
  • Food & beverage$3,04676%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$394,199 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$1,982,858
Medicare patients
1,198
Services billed
20,858

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin107$90,993
JanuviaSitagliptin Phosphate77$69,877
CreonLipase/Protease/Amylase71$61,437
VascepaIcosapent Ethyl143$60,834
ProliaDenosumab28$47,991
EliquisApixaban30$35,861
MyrbetriqMirabegron62$29,516
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate23$28,926
ZenpepLipase/Protease/Amylase20$25,639
Tavaborole22$25,421
OzempicSemaglutide26$24,218
FarxigaDapagliflozin Propanediol16$15,699
LinzessLinaclotide27$15,286
RestasisCyclosporine18$11,452
XareltoRivaroxaban14$11,344

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$250$90,993107 claims
AbbVieCreon, Linzess, Restasis$307$88,174116 claims
MerckJanuvia$118$69,87777 claims
AmgenProlia$196$47,99128 claims
PfizerEliquis$74$35,86130 claims
Novo NordiskOzempic$350$24,21826 claims
AstraZenecaFarxiga$103$15,69916 claims
GSKTrelegy Ellipta, Breo Ellipta$134$13,04826 claims
Johnson & JohnsonXarelto$367$11,34414 claims
Sumitomo Pharma America, Inc.Gemtesa$174$9,48615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Torrance

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →